Looks at real-world use of pacritinib in people with myelofibrosis
Reviews medical records of adults with myelofibrosis treated with pacritinib.
Plain-language title generated from the registry record
Registry title: Pacritinib Effectiveness in Real-world Settings
Key facts
- Where
- Charleston, Columbus, Nashville, New Haven, and Tampa, United StatesSee the 5 sites
Where in United States
- Medical University of South CarolinaCharleston, United StatesTaking people
- The Ohio State UniversityColumbus, United StatesTaking people
- OneOncology Research NetworkNashville, United StatesTaking people
- Yale School of MedicineNew Haven, United StatesTaking people
- Tampa General HospitalTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Swedish Orphan Biovitrum
- Trial code
- NCT07774455
- Record updated
- 21 October 2026
- Original description
This study aims to evaluate real-world treatment patterns and effectiveness of pacritinib, including hematologic and clinical outcomes, and survival through a site-based retrospective chart review of medical records of patients with MF.Read full original descriptionShow less
Pacritinib Effectiveness in Real-world Settings (PACER)
This study aims to evaluate real-world treatment patterns and effectiveness of pacritinib, including hematologic and clinical outcomes, and survival through a site-based retrospective chart review of medical records of patients with MF.
Inclusion: Adult patients must be ≥18 years of age at the index date; Patients diagnosed with MF with platelet counts ≥50 x 109/L at the time of treatment initiation with pacritinib. If multiple values are available within 30 days prior to initiating treatment with pacritinib will use the value closest to index date; Patients will be required to have ≥1 month of treatment with pacritinib and ≥6 months of observation from the start of pacritinib unless the patient died within 6 months of starting pacritinib; If peripheral blasts were evaluated prior to index, they must be <10%. If not evaluated, patients will be included unless a healthcare provider has indicated in the medical record that there is a concern that the patient has transitioned to accelerated/blast phase disease at or prior to index; According to local regulations, waivers of consent will be sought for study patients from the appropriate regulatory authorities and/or the independent ethics committee (IEC)/institutional review board (IRB). For patients not covered by waivers of consent, signed and dated informed consent provided by the patient, or the patient's legally authorized representative(s) for patients under the legal age (with patient assent, as applicable), should be obtained before any study-related activities are undertaken.
Exclusion: Diagnosis of acute myeloid leukemia prior to index; Treated with 2 or more JAK inhibitors prior to initiating treatment with pacritinib; Treated with pacritinib in a clinical trial setting; Physician-concern that the patient has transitioned to accelerated/blast phase disease if peripheral blasts were not evaluated.